D
David Sutton
Researcher at GlaxoSmithKline
Publications - 28
Citations - 2461
David Sutton is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Mitosis & Cell growth. The author has an hindex of 16, co-authored 27 publications receiving 2220 citations.
Papers
More filters
Journal ArticleDOI
GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
Aidan G. Gilmartin,Maureen R. Bleam,Arthur Groy,Katherine G. Moss,Elisabeth A. Minthorn,Swarupa G Kulkarni,Cynthia M. Rominger,Symon G. Erskine,Kelly E. Fisher,Jingsong Yang,Francesca Zappacosta,Roland S. Annan,David Sutton,Sylvie Laquerre +13 more
TL;DR: GSK1120212 combines high potency, selectivity, and long circulating half-life, offering promise for successfully targeting the narrow therapeutic window anticipated for clinical MEK inhibitors.
Journal ArticleDOI
Herpes Simplex Virus Resistance to Acyclovir and Penciclovir after Two Decades of Antiviral Therapy
TL;DR: The prevalence of acyclovir resistance in herpes simplex virus isolates from immunocompetent hosts has remained stable, and in immuncompromised patients, the prevalence of resistant virus has also remained stable but at a higher level.
Journal ArticleDOI
Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin
Steven D. Knight,Nicholas D. Adams,Joelle Lorraine Burgess,Amita M. Chaudhari,Michael G. Darcy,Carla A. Donatelli,Juan I. Luengo,Ken A. Newlander,Cynthia A. Parrish,Lance Ridgers,Martha A. Sarpong,Schmidt Stanley J,Glenn S. Van Aller,Jeffrey D. Carson,Melody Diamond,Patricia A. Elkins,Christine M. Gardiner,Eric Garver,Seth A. Gilbert,Richard R. Gontarek,Jeffrey R. Jackson,Kevin L. Kershner,Lusong Luo,Kaushik Raha,Christian S. Sherk,Chiu-Mei Sung,David Sutton,Peter J. Tummino,Ronald Wegrzyn,Kurt R. Auger,Dashyant Dhanak +30 more
TL;DR: 2,4-Difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3- pyridinyl}benzenesulfonamide (GSK2126458, 1) has been identified as a highly potent, orally bioavailable inhibitor of PI3Kα and mTOR with in vivo activity in both pharmacodynamic and tumor growth efficacy models.
Journal ArticleDOI
Antitumor activity of an allosteric inhibitor of centromere-associated protein-E
Kenneth Wood,Latesh Lad,Lusong Luo,Xiangping Qian,Steven D. Knight,Neysa Nevins,Katjuša Brejc,David Sutton,Aidan G. Gilmartin,Penelope Chua,Radhika Desai,Stephen Schauer,Dean E. McNulty,Roland S. Annan,Lisa D. Belmont,Carmen García,Yan Lee,Melody Diamond,Leo F. Faucette,Michele Giardiniere,Shu-Yun Zhang,Chiu-Mei Sun,Justin D. Vidal,Serge Lichtsteiner,William K. Cornwell,Joel Greshock,Richard Wooster,Jeffrey T. Finer,Robert A. Copeland,Pearl S. Huang,David J. Morgans,Dashyant Dhanak,Gustave Bergnes,Roman Sakowicz,Jeffrey R. Jackson +34 more
TL;DR: Inhibition of CENP-E motor activity in cultured cells and tumor xenografts caused failure of metaphase chromosome alignment and induced mitotic arrest, indicating that tight binding of C Enp-E to microtubules is insufficient to satisfy the mitotic checkpoint.
Journal ArticleDOI
GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models
Mary Ann Hardwicke,Catherine A. Oleykowski,Ramona Plant,Jamin Wang,Qiaoyin Liao,Katherine G. Moss,Ken A. Newlander,Jerry L. Adams,Dashyant Dhanak,Jingsong Yang,Zhihong Lai,David Sutton,Denis R. Patrick +12 more
TL;DR: Results show that GSK1070916 is a potent Aurora B/C kinase inhibitor that has the potential for antitumor activity in a wide range of human cancers.